Search

Johnson and Johnson

Fermé

SecteurSoins de santé

265.58 -0.28

Résumé

Variation du prix de l'action

24h

Actuel

Min

265.33

Max

266.13

Chiffres clés

By Trading Economics

Revenu

299M

5.5B

Ventes

1.2B

25B

P/E

Moyenne du Secteur

31.966

56.597

BPA

2.9

Rendement du dividende

1.88

Marge bénéficiaire

21.865

Employés

138,200

EBITDA

721M

9B

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+7.92% upside

Dividendes

By Acuity

Rendement du dividende

Moyenne du Secteur

1.88%

2.18%

Prochains Résultats

13 oct. 2026

Date du Prochain Dividende

8 déc. 2026

Date du Prochain Détachement de Dividende

24 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

45B

663B

Ouverture précédente

265.86

Clôture précédente

265.58

Sentiment de l'Actualité

By Acuity

29%

71%

57 / 339 Classement par Healthcare

Johnson and Johnson Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 sept. 2026, 00:01 UTC

News
Social Media

Johnson & Johnson shares rose in after-hours trading amid reports of Apollo Global Management discussing a $20 billion acquisition of its DePuy Synthes unit.

11 sept. 2026, 23:41 UTC

News
Social Media

Johnson & Johnson shares higher after news of Apollo Global Management's interest in acquiring its $20 billion orthopedics unit, DePuy Synthes.

10 sept. 2026, 20:07 UTC

Social Media
News

Johnson & Johnson shares are lower despite receiving CE Marking for its ACUVUE OASYS MAX 2-Week lens, with HSBC raising its price target to $320.

9 sept. 2026, 23:01 UTC

Johnson & Johnson shares are higher in after-market trading, reflecting a modest increase since Wednesday's close despite three consecutive sessions of declines.

8 sept. 2026, 20:02 UTC

Social Media

Johnson & Johnson shares are lower today amid declines in the Pharmaceuticals sub-sector, despite strong merger and acquisition capacity estimated at $80 billion.

5 sept. 2026, 00:01 UTC

Johnson & Johnson shares are higher in after-market trading, with no specific news driving the move. The stock reached a session high earlier today.

4 sept. 2026, 20:08 UTC

News

Shares of Johnson & Johnson are lower as Timothy Schmid exercised stock options for 33,597 shares valued at approximately $4.39 million.

3 sept. 2026, 23:41 UTC

News

Johnson & Johnson's shares are lower in after-market trading following FDA approval of IMAAVY and a jury verdict in a talc case.

2 sept. 2026, 23:06 UTC

News

Johnson & Johnson will participate in the Deutsche Bank 2026 Healthcare Summit on September 17. Shares are higher in after-market trading following the announcement.

1 sept. 2026, 20:01 UTC

Johnson & Johnson shares are higher today, reaching the upper end of their one-month trading range during the session. No specific news was identified.

31 août 2026, 23:06 UTC

News

Johnson & Johnson shares are higher in after-market trading following the announcement of an investor conference call on October 13, 2026, for third-quarter results.

29 août 2026, 00:01 UTC

News

Johnson & Johnson shares higher in after-market trading following FDA approval of Stelara for pediatric ulcerative colitis treatment, expanding its market potential.

28 août 2026, 20:08 UTC

Johnson & Johnson shares are higher during Friday's session, reflecting a modest gain since Thursday's close amid routine trading and rising Treasury yields.

27 août 2026, 23:01 UTC

Johnson & Johnson shares advanced in after-market trading, recovering from earlier volatility. Broader market context includes a decline in initial jobless claims.

26 août 2026, 23:06 UTC

Johnson & Johnson shares are lower during after-market hours, reflecting a decline since Wednesday's close amid broader market concerns over persistent inflation pressures.

25 août 2026, 23:06 UTC

Johnson & Johnson shares are lower in after-market trading, reflecting broader market trends and a decline in crude oil prices influencing investor sentiment.

24 août 2026, 19:06 UTC

Social Media
News

Johnson & Johnson's shares are higher today, recovering from earlier volatility and trading above its 20-day moving average near a one-month peak.

21 août 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-hours trading, maintaining a position above the 20-day moving average despite a slight pullback from earlier gains.

20 août 2026, 23:41 UTC

News

Johnson & Johnson shares are higher in after-market trading following operational sales growth and a raised full-year outlook amid recent FDA clearances for its bronchoscopy software.

19 août 2026, 19:32 UTC

News
Social Media

Johnson & Johnson shares advance as EVP Jennifer Taubert exercises options for 15,000 shares valued at $2.38 million and receives regulatory clearance for MONARCH QUEST 3 software.

18 août 2026, 23:56 UTC

Social Media

Johnson & Johnson returns the C-CAR039 program to AbelZeta, while discussions about a potential acquisition of Legend Biotech continue. Shares are roughly flat in after-market trading.

17 août 2026, 23:06 UTC

Johnson & Johnson's shares are roughly flat in after-market trading. The stock remains positioned above its 20-day moving average and near its one-month range.

14 août 2026, 19:46 UTC

Johnson & Johnson shares are lower as pharmaceuticals sub-sector weakness persists. The stock reached a session low earlier before recovering slightly.

13 août 2026, 19:21 UTC

Johnson & Johnson shares are higher, reflecting broader market gains amid stabilizing inflation pressures and a drop in crude oil prices.

12 août 2026, 23:26 UTC

Johnson & Johnson shares are lower in after-market trading, despite initially rising above Wednesday's close. The stock remains above its 20-day moving average.

11 août 2026, 19:26 UTC

Johnson & Johnson shares are lower today, influenced by a downturn in the Pharmaceuticals sub-sector. The stock has shown notable volatility during the session.

10 août 2026, 23:06 UTC

News

Johnson & Johnson will present at the Morgan Stanley Healthcare Conference on September 14, 2026. Shares are roughly flat in after-market trading.

8 août 2026, 00:02 UTC

Johnson & Johnson shares declined in after-market trading, retracing from a brief recovery and currently positioned at the midpoint of their one-month trading range.

7 août 2026, 23:41 UTC

Johnson & Johnson shares are lower in after-market trading, experiencing notable volatility with no specific news identified to explain the movement.

6 août 2026, 23:06 UTC

Johnson & Johnson shares are higher in after-market hours, following a session within its one-month trading range. No specific news was identified for the move.

Comparaison

Variation de prix

Johnson and Johnson prévision

Objectif de Prix

By TipRanks

7.92% hausse

Prévisions sur 12 Mois

Moyen 286.611 USD  7.92%

Haut 320 USD

Bas 260 USD

Basé sur 18 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

18 ratings

14

Achat

4

Maintien

0

Vente

Sentiment

By Acuity

57 / 339Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
help-icon Live chat